Study Summary
This trial is testing a special cell preparation to treat genomically altered lung cancer with a drug called nivolumab.
- Non-Small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer
- Non-small Cell Lung Cancer (NSCLC), Recurrent
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: Up to 5 Years
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
TIL+ Nivolumab
1 of 1
Experimental Treatment
20 Total Participants · 1 Treatment Group
Primary Treatment: TIL+ Nivolumab · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 14 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:- Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN, Noyes DR, Montoya LB, Curry W, Pilon-Thomas SA, Chiappori AA, Tanvetyanon T, Kaye FJ, Thompson ZJ, Yoder SJ, Fang B, Koomen JM, Sarnaik AA, Chen DT, Conejo-Garcia JR, Haura EB, Antonia SJ. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021 Aug;27(8):1410-1418. doi: 10.1038/s41591-021-01462-y. Epub 2021 Aug 12.
- 2022. "Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05681780.
Frequently Asked Questions
Are recruitment efforts still underway for this experiment?
"Correct. According to clinicaltrials.gov, this medical trial was originally posted on December 23rd 2022 and is actively recruiting participants; the study requires 20 individuals from a single centre." - Anonymous Online Contributor
Can you provide the aggregate number of participants currently enrolled in this trial?
"Indeed, the information hosted on clinicaltrials.gov indicates that this medical study is recruiting patients as of December 28th 2022. Initially posted on December 23rd 2020, it seeks to enrol 20 individuals at a single site." - Anonymous Online Contributor